Research digest / about
About Safe Sermorelin
An independent editorial project that reads the sermorelin literature like a transit board — each finding routed back to its source.
What this site is
Safe Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin — the GHRH(1-29) growth-hormone-releasing peptide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The "safe" in the name is a reading posture, not a promise. It signals how we treat the record: route the verified facts to the front, mark the caveats clearly, and leave the empty spaces — where long-term adult data simply do not exist yet — openly unfilled. Where the evidence is strong, we say so; where it thins, we say that too.
Why "safe," and what it does not mean
The domain modifier is editorial framing — a position this publisher occupies relative to the literature, not a claim about the compound's safety in any individual or about services we offer. We do not run a pharmacy, fill prescriptions, or provide consultations. We read studies and report what they measured. Sermorelin's regulatory history is exactly the kind of detail that gets misstated, so we state it plainly: it was an FDA-approved prescription drug for pediatric growth-hormone deficiency, withdrawn from the US market in 2008 for commercial reasons — not safety or efficacy — and it is now prepared by compounding pharmacies as a long-standing Category 1 bulk substance under FDA's Section 503A framework. It is not a currently-marketed FDA-approved finished drug, and it is not a controlled substance.
How we handle the evidence
Every quantitative claim on this site is tied to a numbered citation, and the full list lives on the references page. We distinguish carefully between sermorelin's own data and the data of related GHRH analogs — notably tesamorelin, which carries much of the body-composition and cognition evidence in this drug class. When a number belongs to the analog, we flag it as the analog's, because borrowing it would overstate what is known about sermorelin specifically. That discipline is the entire value of the digest.
What "independent" means here
Independent means we are not selling the conclusion. We have no product to move, no clinic to fill, and no prescription to write, so the digest has no reason to tilt the evidence toward use or away from it. The structure of the site reflects that: a status board that states the regulatory facts plainly, research and body-composition pages that separate what is proven from what is extrapolated, and a references page where every figure can be checked against its source. Where the literature is genuinely uncertain — and for adult, long-term sermorelin use, it is — the honest move is to leave that space visibly open rather than fill it with confidence the studies do not support.